🔗 Visit the ClinicalTrials.gov page for NCT01695239
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Antibodies to watch in 2014. | MAbs | 2013 | 1.14 |
| 2 | Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. | Drugs | 2014 | 1.00 |
| 3 | Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. | Ann Rheum Dis | 2016 | 0.85 |
| 4 | The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. | Auto Immun Highlights | 2014 | 0.83 |
| 5 | Targeted therapies for systemic sclerosis. | Nat Rev Rheumatol | 2013 | 0.82 |
| 6 | Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases. | Postepy Dermatol Alergol | 2016 | 0.75 |